2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
(267) 225-7416
https://www.contexttherapeutics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Martin A. Lehr | Co-Founder, President, CEO & Director | 674,08k | N/D | 1984 |
Ms. Jennifer Minai-Azary | CFO & Treasurer | 504,14k | N/D | 1978 |
Mr. Alex C. Levit Esq. | Chief Legal Officer & Corporate Secretary | 483,83k | N/D | 1979 |
Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | N/D | N/D | N/D |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
L'ISS Governance QualityScore di Context Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.